Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents

Neil Sawhney, Jeffrey W. Moses, Martin B. Leon, Richard E. Kuntz, Jeffrey J. Popma, William Bachinsky, Theodore Bass, Samuel DeMaio, Edward Fry, David Holmes, Paul S. Teirstein

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background - Revascularization strategies often hinge on the presence and degree of left anterior descending coronary artery (LAD) stenosis. A decision for bypass surgery is often based on the durability of surgical LAD revascularization compared with percutaneous approaches. By decreasing restenosis, drug-eluting stents may have reduced the "reintervention gap" between surgery and percutaneous intervention, making the percutaneous route preferable. Methods and Results - Of the 1101 patients in the SIRIUS trial, 459 with an LAD stenosis were randomized to percutaneous intervention with either sirolimus-eluting or bare-metal stents. Baseline demographic, clinical, and angiographic data were obtained. Patients had 1-year clinical and 8-month angiographic follow-up. Baseline characteristics were similar in both groups. The majority of lesions were tubular type B lesions (69.7%) with a mean diameter of 2.73 mm and a mean length of 14.0 mm. The binary in-stent restenosis rate was 2% for the sirolimus stent group and 41.6% for the bare-metal arm (relative risk, 0.05; 95% CI, 0.02 to 0.1; P<0.001). One-year major adverse events (defined as cardiac death, Q-wave and non-Q-wave myocardial infarction, or target vessel revascularization) was decreased 59% in the sirolimus-stent group (9.8% versus 24.9%; relative risk, 0.39; 95% CI, 0.26 to 0.61; P<0.001). Subgroup analysis of 135 patients with proximal LAD lesions showed similar benefits. In-stent restenosis was 0 in the proximal LAD sirolimus-eluting group (n=67), compared with 38% in the bare-metal arm (n=68), and major adverse events demonstrated a similar trend, with a 50% decrease compared with control patients (10.4% versus 20.6%, P=NS). Conclusions - Sirolimus-eluting stents significantly decrease revascularization rates in LAD lesions. At 1 year, sirolimus-eluting stent revascularization rates are comparable to historic single vessel bypass surgery revascularization rates.

Original languageEnglish (US)
Pages (from-to)374-379
Number of pages6
JournalCirculation
Volume110
Issue number4
DOIs
StatePublished - Jul 27 2004

Fingerprint

Sirolimus
Stents
Coronary Artery Disease
Metals
Therapeutics
Drug-Eluting Stents
Coronary Stenosis
Pathologic Constriction
Myocardial Infarction
Demography

Keywords

  • Angioplasty
  • Cardiovascular disease
  • Stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Sawhney, N., Moses, J. W., Leon, M. B., Kuntz, R. E., Popma, J. J., Bachinsky, W., ... Teirstein, P. S. (2004). Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation, 110(4), 374-379. https://doi.org/10.1161/01.CIR.0000136580.34604.B8

Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. / Sawhney, Neil; Moses, Jeffrey W.; Leon, Martin B.; Kuntz, Richard E.; Popma, Jeffrey J.; Bachinsky, William; Bass, Theodore; DeMaio, Samuel; Fry, Edward; Holmes, David; Teirstein, Paul S.

In: Circulation, Vol. 110, No. 4, 27.07.2004, p. 374-379.

Research output: Contribution to journalArticle

Sawhney, N, Moses, JW, Leon, MB, Kuntz, RE, Popma, JJ, Bachinsky, W, Bass, T, DeMaio, S, Fry, E, Holmes, D & Teirstein, PS 2004, 'Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents', Circulation, vol. 110, no. 4, pp. 374-379. https://doi.org/10.1161/01.CIR.0000136580.34604.B8
Sawhney, Neil ; Moses, Jeffrey W. ; Leon, Martin B. ; Kuntz, Richard E. ; Popma, Jeffrey J. ; Bachinsky, William ; Bass, Theodore ; DeMaio, Samuel ; Fry, Edward ; Holmes, David ; Teirstein, Paul S. / Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. In: Circulation. 2004 ; Vol. 110, No. 4. pp. 374-379.
@article{dc0cf31d1e2b4e148407ace2dec70e3b,
title = "Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents",
abstract = "Background - Revascularization strategies often hinge on the presence and degree of left anterior descending coronary artery (LAD) stenosis. A decision for bypass surgery is often based on the durability of surgical LAD revascularization compared with percutaneous approaches. By decreasing restenosis, drug-eluting stents may have reduced the {"}reintervention gap{"} between surgery and percutaneous intervention, making the percutaneous route preferable. Methods and Results - Of the 1101 patients in the SIRIUS trial, 459 with an LAD stenosis were randomized to percutaneous intervention with either sirolimus-eluting or bare-metal stents. Baseline demographic, clinical, and angiographic data were obtained. Patients had 1-year clinical and 8-month angiographic follow-up. Baseline characteristics were similar in both groups. The majority of lesions were tubular type B lesions (69.7{\%}) with a mean diameter of 2.73 mm and a mean length of 14.0 mm. The binary in-stent restenosis rate was 2{\%} for the sirolimus stent group and 41.6{\%} for the bare-metal arm (relative risk, 0.05; 95{\%} CI, 0.02 to 0.1; P<0.001). One-year major adverse events (defined as cardiac death, Q-wave and non-Q-wave myocardial infarction, or target vessel revascularization) was decreased 59{\%} in the sirolimus-stent group (9.8{\%} versus 24.9{\%}; relative risk, 0.39; 95{\%} CI, 0.26 to 0.61; P<0.001). Subgroup analysis of 135 patients with proximal LAD lesions showed similar benefits. In-stent restenosis was 0 in the proximal LAD sirolimus-eluting group (n=67), compared with 38{\%} in the bare-metal arm (n=68), and major adverse events demonstrated a similar trend, with a 50{\%} decrease compared with control patients (10.4{\%} versus 20.6{\%}, P=NS). Conclusions - Sirolimus-eluting stents significantly decrease revascularization rates in LAD lesions. At 1 year, sirolimus-eluting stent revascularization rates are comparable to historic single vessel bypass surgery revascularization rates.",
keywords = "Angioplasty, Cardiovascular disease, Stents",
author = "Neil Sawhney and Moses, {Jeffrey W.} and Leon, {Martin B.} and Kuntz, {Richard E.} and Popma, {Jeffrey J.} and William Bachinsky and Theodore Bass and Samuel DeMaio and Edward Fry and David Holmes and Teirstein, {Paul S.}",
year = "2004",
month = "7",
day = "27",
doi = "10.1161/01.CIR.0000136580.34604.B8",
language = "English (US)",
volume = "110",
pages = "374--379",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents

AU - Sawhney, Neil

AU - Moses, Jeffrey W.

AU - Leon, Martin B.

AU - Kuntz, Richard E.

AU - Popma, Jeffrey J.

AU - Bachinsky, William

AU - Bass, Theodore

AU - DeMaio, Samuel

AU - Fry, Edward

AU - Holmes, David

AU - Teirstein, Paul S.

PY - 2004/7/27

Y1 - 2004/7/27

N2 - Background - Revascularization strategies often hinge on the presence and degree of left anterior descending coronary artery (LAD) stenosis. A decision for bypass surgery is often based on the durability of surgical LAD revascularization compared with percutaneous approaches. By decreasing restenosis, drug-eluting stents may have reduced the "reintervention gap" between surgery and percutaneous intervention, making the percutaneous route preferable. Methods and Results - Of the 1101 patients in the SIRIUS trial, 459 with an LAD stenosis were randomized to percutaneous intervention with either sirolimus-eluting or bare-metal stents. Baseline demographic, clinical, and angiographic data were obtained. Patients had 1-year clinical and 8-month angiographic follow-up. Baseline characteristics were similar in both groups. The majority of lesions were tubular type B lesions (69.7%) with a mean diameter of 2.73 mm and a mean length of 14.0 mm. The binary in-stent restenosis rate was 2% for the sirolimus stent group and 41.6% for the bare-metal arm (relative risk, 0.05; 95% CI, 0.02 to 0.1; P<0.001). One-year major adverse events (defined as cardiac death, Q-wave and non-Q-wave myocardial infarction, or target vessel revascularization) was decreased 59% in the sirolimus-stent group (9.8% versus 24.9%; relative risk, 0.39; 95% CI, 0.26 to 0.61; P<0.001). Subgroup analysis of 135 patients with proximal LAD lesions showed similar benefits. In-stent restenosis was 0 in the proximal LAD sirolimus-eluting group (n=67), compared with 38% in the bare-metal arm (n=68), and major adverse events demonstrated a similar trend, with a 50% decrease compared with control patients (10.4% versus 20.6%, P=NS). Conclusions - Sirolimus-eluting stents significantly decrease revascularization rates in LAD lesions. At 1 year, sirolimus-eluting stent revascularization rates are comparable to historic single vessel bypass surgery revascularization rates.

AB - Background - Revascularization strategies often hinge on the presence and degree of left anterior descending coronary artery (LAD) stenosis. A decision for bypass surgery is often based on the durability of surgical LAD revascularization compared with percutaneous approaches. By decreasing restenosis, drug-eluting stents may have reduced the "reintervention gap" between surgery and percutaneous intervention, making the percutaneous route preferable. Methods and Results - Of the 1101 patients in the SIRIUS trial, 459 with an LAD stenosis were randomized to percutaneous intervention with either sirolimus-eluting or bare-metal stents. Baseline demographic, clinical, and angiographic data were obtained. Patients had 1-year clinical and 8-month angiographic follow-up. Baseline characteristics were similar in both groups. The majority of lesions were tubular type B lesions (69.7%) with a mean diameter of 2.73 mm and a mean length of 14.0 mm. The binary in-stent restenosis rate was 2% for the sirolimus stent group and 41.6% for the bare-metal arm (relative risk, 0.05; 95% CI, 0.02 to 0.1; P<0.001). One-year major adverse events (defined as cardiac death, Q-wave and non-Q-wave myocardial infarction, or target vessel revascularization) was decreased 59% in the sirolimus-stent group (9.8% versus 24.9%; relative risk, 0.39; 95% CI, 0.26 to 0.61; P<0.001). Subgroup analysis of 135 patients with proximal LAD lesions showed similar benefits. In-stent restenosis was 0 in the proximal LAD sirolimus-eluting group (n=67), compared with 38% in the bare-metal arm (n=68), and major adverse events demonstrated a similar trend, with a 50% decrease compared with control patients (10.4% versus 20.6%, P=NS). Conclusions - Sirolimus-eluting stents significantly decrease revascularization rates in LAD lesions. At 1 year, sirolimus-eluting stent revascularization rates are comparable to historic single vessel bypass surgery revascularization rates.

KW - Angioplasty

KW - Cardiovascular disease

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=3242890567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242890567&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000136580.34604.B8

DO - 10.1161/01.CIR.0000136580.34604.B8

M3 - Article

C2 - 15249503

AN - SCOPUS:3242890567

VL - 110

SP - 374

EP - 379

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -